Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis
Acute tubular interstitial nephritis (ATIN) is the most frequently reported pathology in patients with checkpoint inhibitor (CPI) induced acute kidney injury (AKI).Glucocorticoid (GC) therapy and discontinuation of CPI are the mainstay of treatment to prevent permanent renal dysfunction and dialysis.However, less than 50% of patients have complete